The influence of cyclin D1 (CCND1) 870A>G polymorphism and CCND1-thymidylate synthase (TS) gene -: gene interaction on the outcome of childhood acute lymphoblastic leukaemia

被引:35
作者
Costea, I
Moghrabi, A
Krajinovic, M
机构
[1] Univ Montreal, Ctr Rech, Hop St Justine, Dept Pediat, Montreal, PQ H3T 1C5, Canada
[2] Ctr Cancerol Charles Bruneau, Serv Hematooncol, Montreal, PQ, Canada
来源
PHARMACOGENETICS | 2003年 / 13卷 / 09期
关键词
childhood ALL; disease outcome; event-free survival; cyclin D1; thymidylate synthase; polymorphism;
D O I
10.1097/00008571-200309000-00006
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The 870A>G polymorphism in the cyclin D1 (CCND1) gene modulates mRNA splicing, leading to altered protein that may affect the regulation of the G1/S cell-cycle checkpoint. This polymorphism has been reported to influence susceptibility to and progression of several malignancies. Furthermore, the change of retinoblastoma protein regulation mediated by CCND1 may play a role in the development of methotrexate (MTX) resistance via an associated higher activity of enzymes that are inhibited by MTX. This study shows that children with acute lymphoblastic leukaemia (ALL) who are homozygous for the CCND1 A variant have a lower probability of event-free survival (P = 0.006) compared to carriers of the G variant. A significant result is retained in the presence of other prognostic factors. This impact is even more apparent in individuals who are also homozygous for thymidylate synthase (TS) triple repeat (P < 0.00005), which has previously been shown to influence the outcome of childhood ALL. (C) 2003 Lippincott Williams Wilkins.
引用
收藏
页码:577 / 580
页数:4
相关论文
共 17 条
[1]  
BARTKOVA J, 1995, ONCOGENE, V10, P775
[2]  
BETTICHER DC, 1995, ONCOGENE, V11, P1005
[3]   Intrinsic and acquired resistance to methotrexate in acute leukemia [J].
Gorlick, R ;
Goker, E ;
Trippett, T ;
Waltham, M ;
Banerjee, D ;
Bertino, JR .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (14) :1041-1048
[4]   Effect of cyclin D1 overexpression on drug sensitivity in a human fibrosarcoma cell line [J].
Hochhauser, D ;
Schnieders, B ;
ErcikanAbali, E ;
Gorlick, R ;
MuiseHelmericks, R ;
Li, WW ;
Fan, JG ;
Banerjee, D ;
Bertino, JR .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (18) :1269-1275
[5]   ABSENCE OF CYCLIN D1/PRAD1 POINT MUTATIONS IN HUMAN BREAST CANCERS AND PARATHYROID ADENOMAS AND IDENTIFICATION OF A NEW CYCLIN D1 GENE POLYMORPHISM [J].
HOSOKAWA, Y ;
TU, T ;
TAHARA, H ;
SMITH, AP ;
ARNOLD, A .
CANCER LETTERS, 1995, 93 (02) :165-170
[6]  
Howe D, 2001, HAEMATOLOGICA, V86, P563
[7]  
Kong SM, 2000, CANCER RES, V60, P249
[8]   Polymorphism of the thymidylate synthase gene and outcome of acute lymphoblastic leukaemia [J].
Krajinovic, M ;
Costea, I ;
Chiasson, S .
LANCET, 2002, 359 (9311) :1033-1034
[9]   Genetic polymorphism of thiopurine S-methyltransferase: Molecular mechanisms and clinical importance [J].
Krynetski, EY ;
Evans, WE .
PHARMACOLOGY, 2000, 61 (03) :136-146
[10]   Rapid detection of CYP1A1, CYP2D6, and NAT variants by multiplex polymerase chain reaction and allele-specific oligonucleotide assay [J].
Labuda, D ;
Krajinovic, M ;
Richer, C ;
Skoll, A ;
Sinnett, H ;
Yotova, V ;
Sinnett, D .
ANALYTICAL BIOCHEMISTRY, 1999, 275 (01) :84-92